Browse articles on EyeWorld.org from the Cornea section. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Is DSAEK being taught less and less to surgeons in training in favor of DMEK? Three physicians shared their thoughts on the status of these two procedures in training programs and in practice.
Cornea Editor Julie Schallhorn, MD, discusses the importance of the in-person education that physicians will find at the ASCRS Annual Meeting and previews the articles in the Cornea section of the issue.
Bala Ambati, MD, won The Winning Pitch Challenge during the session at the ASCRS Annual Meeting in 2019. His company, iVeena, presented the IVMED-80, a pharmacologic drop treatment for keratoconus.
At The Winning Pitch Challenge in 2020, the top prize went to Sunil Shah, MD, presenting on Photon Therapeutics and its device for ultraviolet light treatment for corneal infections. Simon Dean, MBChB, MSc, spoke with EyeWorld about the company’s technology and updates since winning the competition.
The use of autologous blood eye drops continues to be a point of interest in research and as a potential cost-effective alternative to processed hemoderivatives. A recent study published in the journal Clinical Ophthalmology continues to advance the topic.
Cornea Editor Clara Chan, MD, described how innovation, progression, and disruption keep the field evolving and introduced the new Cornea Editor, Julie Schallhorn, MD.
For the last decade, interferon alpha-2b was the preferred pharmacologic therapy for ocular surface squamous neoplasia (OSSN) in the U.S. However, with the pandemic, the makers of interferon transitioned its use for treatment of COVID-19 patients instead. This article covers other OSSN treatment options.
When treating endothelial dysfunction, surgeons have several options. The current standard of care is endothelial keratoplasty, DSAEK and DMEK. One new therapy that has been getting a lot of attention is corneal endothelial cell therapy, and there has been significant progress in the last 18 months.
The push for widespread COVID-19 vaccination has renewed the focus on the side effects that vaccines may have. It’s an especially unique situation due to the distinct timeframe for this mass vaccination campaign. Two experts spoke about potential ocular impacts of the vaccine and what physicians should look for.
During a session at the 2022 AAO Annual Meeting, Christopher Rapuano, MD, and Sonia Yoo, MD, debated the best way to surgically manage recurrent corneal erosions. The audience was polled ahead of the presentations, with 65% indicating that they thought epithelial debridement with diamond burr polishing of Bowman’s layer is better; 25% said that PTK is better.